Abstract Background A35 is a novel synthetic cyclizing-berberine recently patented as an antitumor compound. In this study we further explored the biological effects and mechanisms of A As a dual topoisomerase inhibitor characterized by no cardiac toxicity, A35 is a promising topoisomerase anticancer agent and worthy of further development in future. Irrespective of the envelope, the greenhorn offers quite appropriate internal ADVANCE A35 for the creation of a modern PC system. It also has a removable FlexCage drive bay. Internal[…]
